Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
NCT ID: NCT00602680
Last Updated: 2009-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
1 participants
INTERVENTIONAL
2008-01-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT01266525
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT02660983
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
NCT02064920
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
NCT00777608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
dose 1
SSR180711C
duration of treatment: 4 weeks
2
dose 2
SSR180711C
duration of treatment: 4 weeks
3
dose 3
SSR180711C
duration of treatment: 4 weeks
4
placebo
duration of treatment: 4 weeks
5
donepezil
duration of treatment: 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SSR180711C
duration of treatment: 4 weeks
donepezil
duration of treatment: 4 weeks
placebo
duration of treatment: 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Medical condition which may interfere with the study
* History of epileptic seizures
* Lens opacity
* Lack of reliable caregiver
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruno DUBOIS, MD
Role: STUDY_CHAIR
Scientific Advisory Committee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-Aventis Administrative Office
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSR180711
Identifier Type: -
Identifier Source: secondary_id
EudraCT 2007-001639-80
Identifier Type: -
Identifier Source: secondary_id
PDY10400
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.